The application of Russell and Burch 3R principle in rodent models of neurodegenerative disease: The case of Parkinson’s disease
暂无分享,去创建一个
Augusto Vitale | Flavia Chiarotti | Enrico Alleva | Giovanni Laviola | Gemma Calamandrei | E. Alleva | G. Calamandrei | G. Laviola | F. Chiarotti | A. Manciocco | Arianna Manciocco | A. Vitale | Arianna Manciocco
[1] A. Blackburn,et al. Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.
[2] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[3] Suzanne Imbriglio. Environmental Enrichment Slows Disease Progression in R6/2 Huntingtonʼs Disease Mice. , 2002 .
[4] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[5] B. Spruijt,et al. Access to enriched housing is rewarding to rats as reflected by their anticipatory behaviour , 2003, Animal Behaviour.
[6] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[7] T. Di Paolo,et al. Stereospecific prevention by 17β‐estradiol of MPTP‐induced dopamine depletion in mice , 2000, Synapse.
[8] J. O'Callaghan,et al. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. , 1998, Annals of the New York Academy of Sciences.
[9] B. Spruijt,et al. Isolation changes the incentive value of sucrose and social behaviour in juvenile and adult rats , 1999, Behavioural Brain Research.
[10] B. Szekely,et al. Adjunctive treatment in Parkinson's disease: physical therapy and comprehensive group therapy. , 1982, Rehabilitation literature.
[11] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[12] Michael J. Campbell,et al. Statistical tables for the design of clinical trials , 1987 .
[13] G. Barrie Wetherill,et al. Sequential methods in statistics , 1967 .
[14] V. Russell,et al. Voluntary Running Provides Neuroprotection in Rats After 6-Hydroxydopamine Injection into the Medial Forebrain Bundle , 2004, Metabolic Brain Disease.
[15] S. Lewis,et al. Cognitive Deficits and Psychosis in Parkinson’s Disease , 2006, CNS drugs.
[16] A. Tamas,et al. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats , 2005, Behavioural Brain Research.
[17] E. Masliah,et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. , 2000, The American journal of pathology.
[18] Saber M Hussain,et al. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[19] U. Ungerstedt. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. , 1971, Acta physiologica Scandinavica. Supplementum.
[20] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[21] S. Thobois,et al. Génétique et facteurs environnementaux de la maladie de Parkinson , 2002 .
[22] J. Trojanowski,et al. Transgenic Models of Tauopathies and Synucleinopathies , 1999, Brain pathology.
[23] Joseph P Huston,et al. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.
[24] A. Barnekow,et al. Effects of different forms of environmental enrichment on behavioral, endocrinological, and immunological parameters in male mice , 2003, Hormones and Behavior.
[25] V. Baumans,et al. Strain specific behavioural response to environmental enrichment in the mouse. , 1994, Journal of experimental animal science.
[26] Linda MacDonald Glenn. When pigs fly? Legal and ethical issues in transgenics and the creation of chimeras. The Walter C. Randall Biomedical Ethics Lecture. , 2003, The Physiologist.
[27] H. W. Schultz. Animal Welfare Act , 1981 .
[28] I. Date,et al. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis , 1990, Brain Research.
[29] Augusto Vitale,et al. The 3R principle and the use of non-human primates in the study of neurodegenerative diseases: The case of Parkinson's disease , 2009, Neuroscience & Biobehavioral Reviews.
[30] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[31] E. Masliah,et al. α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .
[32] F. Gage,et al. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine , 2000, Brain Research.
[33] Marten P. Smidt,et al. Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice , 2006, Proceedings of the National Academy of Sciences.
[34] M. Youdim,et al. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[35] Anticipation of play elicits high-frequency ultrasonic vocalizations in young rats. , 1998 .
[36] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[37] T. Dawson. Parkin and defective ubiquitination in Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.
[38] R. Behringer,et al. Manipulating the Mouse Embryo: A Laboratory Manual , 2002 .
[39] J. Engele,et al. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia [published erratum appears in J Neurosci 1992 Mar;12(3):685] , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[40] MoonHee Lee,et al. Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .
[41] G. Petzinger,et al. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.
[42] R. McKay,et al. A Specific Survival Response in Dopamine Neurons at Most Risk in Parkinson's Disease , 2006, The Journal of Neuroscience.
[43] M. Zigmond,et al. Forced Limb-Use Effects on the Behavioral and Neurochemical Effects of 6-Hydroxydopamine , 2001, The Journal of Neuroscience.
[44] Alena Savonenko,et al. Transgenic mouse models of neurodegenerative disease: Opportunities for therapeutic development , 2002, Current neurology and neuroscience reports.
[45] Makoto Hashimoto,et al. Transgenic Models of α‐Synuclein Pathology , 2003 .
[46] T. Sherer,et al. Mechanistic Approaches to Parkinson's Disease Pathogenesis , 2002, Brain pathology.
[47] H. Würbel. Publications should include an animal-welfare section , 2007, Nature.
[48] Dwaine F Emerich,et al. Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task , 1997, Behavioural Brain Research.
[49] David C. Dorman,et al. Manganese Dosimetry: Species Differences and Implications for Neurotoxicity , 2005, Critical reviews in toxicology.
[50] G. Bignami. From entropy to Duino , 1999, Nature.
[51] V. Baumans,et al. Do Male Mice Prefer or Avoid Each Other's Company? Influence of Hierarchy, Kinship, and Familiarity , 2001 .
[52] K. Takata,et al. Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsonian flatworm model. , 2003, Journal of pharmacological sciences.
[53] J. Trojanowski,et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.
[54] G. Yancopoulos,et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.
[55] K. Unsicker,et al. Glial Cell Line-Derived Neurotrophic Factor Requires Transforming Growth Factor-β for Exerting Its Full Neurotrophic Potential on Peripheral and CNS Neurons , 1998, The Journal of Neuroscience.
[56] P. Brain,et al. Refining rodent husbandry: the mouse: Report of the Rodent Refinement Working Party , 1998, Laboratory animals.
[57] M. Youdim,et al. Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition , 2005, Journal of neurochemistry.
[58] K. S. Bankiewicz,et al. A 6-hydroxydopamine-induced selective parkinsonian rat model , 1989, Brain Research.
[59] Satoru Kobayashi,et al. Effects of enriched environments with different durations and starting times on learning capacity during aging in rats assessed by a refined procedure of the Hebb‐Williams maze task , 2002, Journal of neuroscience research.
[60] C. Sherwin,et al. Housing conditions affect self-administration of anxiolytic by laboratory mice , 2004, Animal Welfare.
[61] J. Salamone,et al. Involvement of ventrolateral striatal dopamine in movement initiation and execution: A microdialysis and behavioral investigation , 1996, Neuroscience.
[62] Jos Prickaerts,et al. Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.
[63] J. B. Justice,et al. Dopamine depletion in a striatal subregion disrupts performance of a skilled motor task in the rat , 1985, Brain Research.
[64] M. Hoane,et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats , 1999, Behavioural Brain Research.
[65] Qin Li,et al. The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of l-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease , 2008, The Journal of Neuroscience.
[66] Y. Kitamura,et al. Neuroprotective Mechanisms of Antiparkinsonian Dopamine D2-Receptor Subfamily Agonists , 2003, Neurochemical Research.
[67] R. Richardson,et al. Effects of Environmental Enrichment on Rate of Contextual Processing and Discriminative Ability in Adult Rats , 2000, Neurobiology of Learning and Memory.
[68] C. J. Moore,et al. Transgenesis and Animal Welfare , 1995, Alternatives to laboratory animals : ATLA.
[69] B. Halliwell,et al. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. , 2001, Journal of neurochemistry.
[70] Patrick Bateson,et al. When to experiment on animals. , 1986, New scientist.
[71] W. Russell,et al. Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.
[72] Mark R. Rosenzweig,et al. Enriched and impoverished environments , 1987 .
[73] D. Dluzen,et al. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. , 1996, Neurotoxicology and teratology.
[74] B. Costall,et al. Neurotoxic Sesquiterpenoids from the Yellow Star Thistle Centaurea solstitialis L. (Asteraceae) , 1991 .
[75] I. Olsson,et al. Improving housing conditions for laboratory mice: a review of 'environmental enrichment' , 2002, Laboratory animals.
[76] P. Brain,et al. Re®ning rodent husbandry: the mouse , 1998 .
[77] J. Balcombe,et al. Laboratory environments and rodents' behavioural needs: a review , 2006, Laboratory animals.
[78] P. Barnéoud,et al. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat , 1995, Neuroscience.
[79] L. Tremblay,et al. Experimental Models of Parkinson’s Disease , 2002, Annales pharmaceutiques francaises.
[80] G. Calamandrei. Ethological and methodological considerations in the use of newborn rodents in biomedical research. , 2004, Annali dell'Istituto superiore di sanita.
[81] C. C. Johnson,et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.
[82] Anders Björklund,et al. Prospects for new restorative and neuroprotective treatments in Parkinson's disease , 1999, Nature.
[83] M. Chesselet,et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[84] K. Murray,et al. Phenotyping of genetically engineered mice: humane, ethical, environmental, and husbandry issues. , 2006, ILAR journal.
[85] E. J. Green,et al. Therapeutic Effects of Environmental Enrichment on Cognitive Function and Tissue Integrity Following Severe Traumatic Brain Injury in Rats , 2001, Experimental Neurology.
[86] T. Voss,et al. Effects of environmental enrichment on aggressive behavior, dominance hierarchies, and endocrine states in male DBA/2J mice , 1994, Physiology & Behavior.
[87] D. Harper,et al. Journal of Applied Animal Welfare Science Behavioral Indexes of Poor Welfare in Laboratory Rats , 2022 .
[88] A. M. Snyder,et al. Stress‐induced neurological impairments in an animal model of parkinsonism , 1985, Annals of neurology.
[89] Patrick Bateson,et al. Assessment of pain in animals , 1991, Animal Behaviour.
[90] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[91] C. Barnard,et al. Housing and welfare in laboratory rats: time-budgeting and pathophysiology in single-sex groups , 1996, Animal Behaviour.
[92] G. Koob,et al. Extended Access to Nicotine Self-Administration Leads to Dependence: Circadian Measures, Withdrawal Measures, and Extinction Behavior in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.
[93] T. Sherer,et al. Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[94] Jonathan Salcedo,et al. Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein , 2004, The Journal of Neuroscience.
[95] L. V. Zutphen,et al. Nesting Material as Environmental Enrichment Has No Adverse Effects on Behavior and Physiology of Laboratory Mice , 1997, Physiology & Behavior.
[96] F. Archibald,et al. Manganese poisoning and the attack of trivalent manganese upon catecholamines. , 1987, Archives of biochemistry and biophysics.
[97] A. Still,et al. On the number of subjects used in animal behaviour experiments , 1982, Animal Behaviour.
[98] A. Björklund,et al. l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function , 2002, Neurobiology of Disease.
[99] T. Robbins,et al. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention , 1985, Nature.
[100] H. Würbel. Ideal homes? Housing effects on rodent brain and behaviour , 2001, Trends in Neurosciences.
[101] I. Whishaw,et al. Disruption of central cholinergic systems in the rat by basal forebrain lesions or atropine: Effects on feeding, sensorimotor behaviour, locomotor activity and spatial navigation , 1985, Behavioural Brain Research.
[102] T. Wolfle. Introduction: environmental enrichment. , 2005, ILAR journal.
[103] J. Talling,et al. Familiarity increases consistency in animal tests , 2005, Behavioural Brain Research.
[104] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[105] Thomas Hartung,et al. Workgroup Report: Incorporating In Vitro Alternative Methods for Developmental Neurotoxicity into International Hazard and Risk Assessment Strategies , 2007, Environmental health perspectives.
[106] Y. Agid,et al. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.
[107] Brian Knutson,et al. Anticipation of play elicits high-frequency ultrasonic vocalizations in young rats. , 1998, Journal of comparative psychology.
[108] M. Chesselet,et al. Alpha-synuclein and transgenic mouse models , 2004, Neurobiology of Disease.
[109] S. Vandewoude,et al. Species-specific assessment of pain in laboratory animals. , 2003, Contemporary topics in laboratory animal science.
[110] Hua-qing Liu,et al. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease. , 2006, Biomaterials.
[111] A. Hannan,et al. Effects of enriched environment on animal models of neurodegenerative diseases and psychiatric disorders , 2008, Neurobiology of Disease.
[112] Makoto Hashimoto,et al. Transgenic models of alpha-synuclein pathology: past, present, and future. , 2003, Annals of the New York Academy of Sciences.
[113] K. Unsicker,et al. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[114] C. Sortwell,et al. Diminished Survival of Mesencephalic Dopamine Neurons Grafted into Aged Hosts Occurs during the Immediate Postgrafting Interval , 2001, Experimental Neurology.
[115] Gerd Kempermann,et al. Regional effects of wheel running and environmental enrichment on cell genesis and microglia proliferation in the adult murine neocortex. , 2003, Cerebral cortex.
[116] C. Barnard,et al. Housing and welfare in laboratory rats: effects of cage stocking density and behavioural predictors of welfare , 1999, Animal Behaviour.
[117] Roger M. Nitsch,et al. Laboratory animal welfare: Cage enrichment and mouse behaviour , 2004, Nature.
[118] H. Buchanan-Smith,et al. Harmonising the definition of refinement , 2005, Animal Welfare.
[119] M. Chesselet,et al. Genetic mouse models of parkinsonism: Strengths and limitations , 2005, NeuroRX.
[120] R. Morris. Spatial Localization Does Not Require the Presence of Local Cues , 1981 .
[121] G. Wooten,et al. Are men at greater risk for Parkinson’s disease than women? , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[122] L. Hurley. The roles of trace elements in foetal and neonatal development. , 1981, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[123] S Shimohama,et al. The parkinsonian models: invertebrates to mammals. , 2000, Japanese journal of pharmacology.
[124] A. Björklund,et al. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.
[125] M. Yang,et al. Environmental enrichment: effects on stereotyped behavior and regional neuronal metabolic activity , 2002, Brain Research.
[126] T. Azar,et al. Stress-like responses to common procedures in male rats housed alone or with other rats. , 2002, Contemporary topics in laboratory animal science.
[127] Mepham Tb,et al. Transgenesis and animal welfare. , 1995 .
[128] E. Masliah,et al. Transgenic animal models of neurodegenerative diseases and their application to treatment development. , 2007, Advanced drug delivery reviews.
[129] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[130] Bengt Winblad,et al. Dopaminergic Deficiency is More Pronounced in Putamen than in Nucleus Caudatus in Parkinson's Disease , 1983 .
[131] G. B. Wetherill,et al. Sequential Methods in Statistics. , 1972 .
[132] P. Townsend. Use of in-cage shelters by laboratory rats , 1997 .
[133] G. Jackson,et al. Drosophila models of neurodegenerative disease , 2005, NeuroRX.
[134] T. Schallert,et al. Reactive capacity: A sensitive behavioral marker of movement initiation and nigrostriatal dopamine function , 1985, Brain Research.
[135] J. Panksepp,et al. Tickling induces reward in adolescent rats , 2001, Physiology & Behavior.
[136] Y. Mitsumoto,et al. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice , 2006, Neuroscience Letters.
[137] L. Ricceri,et al. Refining learning and memory assessment in laboratory rodents. An ethological perspective. , 2004, Annali dell'Istituto superiore di sanita.
[138] C. Stichel,et al. The mouse MPTP model: gene expression changes in dopaminergic neurons , 2003, The European journal of neuroscience.
[139] B. Davidson,et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat , 1999, Gene Therapy.
[140] R. Schwarz,et al. Patterns of psychological problems in Parkinson's disease , 2005, Acta neurologica Scandinavica.
[141] W. Langhans,et al. Enrichment-dependent differences in novelty exploration in rats can be explained by habituation , 2001, Behavioural Brain Research.
[142] Penny Hawkins,et al. Recognizing and assessing pain, suffering and distress in laboratory animals: a survey of current practice in the UK with recommendations , 2002, Laboratory animals.
[143] L. Stehno-Bittel,et al. Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of Parkinsonism with severe neurodegeneration , 2007, Neuroscience.
[144] T. Schallert,et al. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson’s disease: antiparkinson effects of Sinemet and protective effects of methylphenidate , 2005, Behavioural Brain Research.
[145] J. W. Rudy,et al. Brief exposure to an enriched environment improves performance on the Morris water task and increases hippocampal cytosolic protein kinase C activity in young rats , 1992, Behavioural Brain Research.
[146] David G. Porter,et al. Ethical scores for animal experiments , 1992, Nature.
[147] P. H. Griffiths,et al. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment , 1985, Veterinary Record.
[148] G. Miller,et al. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease , 2003, Neuroscience.
[149] Douglas G Altman,et al. Guidelines for the design and statistical analysis of experiments using laboratory animals. , 2002, ILAR journal.
[150] A. Björklund,et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[151] E. Alleva,et al. Problems of test choice and data analysis in behavioral teratology: the case of prenatal benzodiazepines. , 1987, Neurotoxicology and teratology.
[152] P. Riederer,et al. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man , 2005, Journal of Neural Transmission.
[153] J. Cummings,et al. Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.
[154] S. Dunnett,et al. Differential effects of unilateral striatal and nigrostriatal lesions on grip strength, skilled paw reaching and drug-induced rotation in the rat , 2001, Brain Research Bulletin.
[155] M Puopolo,et al. Behavioural effects of endocrine disrupting chemicals on laboratory rodents: statistical methodologies and an application concerning developmental PCB exposure. , 1999, Chemosphere.
[156] S. Wachtel,et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions , 1999, Neuroscience.
[157] D. Broom,et al. Investigations into the preferences of laboratory rats for nest-boxes and nesting materials , 1998, Laboratory animals.
[158] T. Humby,et al. Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease , 2006, The European journal of neuroscience.
[159] S. Markey,et al. MPTP toxicity: implications for research in Parkinson's disease. , 1988, Annual review of neuroscience.
[160] Todd B. Sherer,et al. Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.
[161] Elissa J. Chesler,et al. Influences of laboratory environment on behavior , 2002, Nature Neuroscience.
[162] T. Sherer,et al. Pathogenesis of Parkinson's disease. , 2001, Current opinion in investigational drugs.
[163] S. Kish,et al. Brain neurotransmitters in dystonia musculorum deformans. , 1986, The New England journal of medicine.
[164] J. Langston,et al. Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.
[165] H. Teräväinen,et al. Animal models of parkinsonism. , 1990, Pharmacology & toxicology.
[166] T. Poole,et al. Happy animals make good science , 1997, Laboratory animals.
[167] M. Emborg. Evaluation of animal models of Parkinson's disease for neuroprotective strategies , 2004, Journal of Neuroscience Methods.
[168] P. Jenner,et al. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.
[169] V. Russell,et al. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease , 2005, Behavioural Brain Research.
[170] C. Markham,et al. Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry , 1986, Brain Research.
[171] S. Speciale,et al. MPTP: insights into parkinsonian neurodegeneration. , 2002, Neurotoxicology and teratology.
[172] M. Chesselet,et al. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype α-synuclein , 2006, Neuroscience.
[173] T. Oury,et al. Manganese Superoxide Dismutase Protects against 6-Hydroxydopamine Injury in Mouse Brains* , 2005, Journal of Biological Chemistry.
[174] E. Hirsch. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. , 2000, Annals of neurology.
[175] C. Sortwell,et al. Diminished Viability, Growth, and Behavioral Efficacy of Fetal Dopamine Neuron Grafts in Aging Rats with Long-Term Dopamine Depletion: An Argument for Neurotrophic Supplementation , 1999, The Journal of Neuroscience.
[176] E. Patterson-Kane. Cage Size Preference in Rats in the Laboratory , 2002, Journal of applied animal welfare science : JAAWS.